Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106380 | 0.87 | JAK2 (0.53) | JAK2NTRK1NPC1KDM4EALDH1A1 | |
| SCHEMBL4293207 | 0.86 | JAK2 (0.53) | JAK2NTRK1NPC1KDM4EALDH1A1 | |
| SCHEMBL16426170 | 0.82 | L3MBTL3 (0.39) | JAK2NTRK1KDM4EALDH1A1HRH3 | |
| SCHEMBL24775508 | 0.76 | SLC6A4 (0.49) | NPC1KDM4EALDH1A1SLC6A4HRH3 | |
| SCHEMBL1075746 | 0.76 | JAK2 (0.55) | JAK2NTRK1KDM4EALDH1A1SLC6A4 | |
| SCHEMBL19560119 | 0.75 | JAK2 (0.44) | JAK2NTRK1NPC1KDM4EALDH1A1 | |
| SCHEMBL4100620 | 0.75 | NPC1 (0.48) | NPC1KDM4EALDH1A1HRH3POLB | |
| SCHEMBL16426169 | 0.74 | JAK2 (0.49) | JAK2NTRK1POLBMEN1KMT2A | |
| SCHEMBL12943762 | 0.73 | POLB (0.57) | NPC1KDM4EALDH1A1HRH3POLB | |
| SCHEMBL4106214 | 0.73 | JAK2 (0.53) | JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharm Inc. (US) | 2019-04-09 | — | — | US | disclosed |
| US-9796724-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | JAK2 124/4885NTRK1 7/4885NPC1 3943/4885 |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | TXK, FRK, LTK | JAK2 124/4885NTRK1 7/4885NPC1 3943/4885 |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | JAK2 124/4885NTRK1 7/4885NPC1 3943/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | JAK2 143/4885NTRK1 8/4885NPC1 4005/4885 |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | TXK, FRK, LTK | JAK2 124/4885NTRK1 7/4885NPC1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.